Favorable News Coverage Somewhat Unlikely to Impact Second Sight Medical (NASDAQ:EYES) Share Price

Headlines about Second Sight Medical (NASDAQ:EYES) have trended positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Second Sight Medical earned a news impact score of 0.26 on Accern’s scale. Accern also gave media stories about the medical device company an impact score of 49.1113586848759 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Shares of EYES stock traded down $0.05 during trading on Monday, hitting $1.74. 30,267 shares of the stock traded hands, compared to its average volume of 590,926. The firm has a market cap of $107.15, a PE ratio of -3.03 and a beta of 3.02. Second Sight Medical has a 52-week low of $0.90 and a 52-week high of $2.58.

How to Become a New Pot Stock Millionaire

Second Sight Medical (NASDAQ:EYES) last posted its earnings results on Wednesday, March 7th. The medical device company reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.01. The firm had revenue of $3.10 million during the quarter, compared to the consensus estimate of $1.98 million. Second Sight Medical had a negative net margin of 358.06% and a negative return on equity of 197.61%. The firm’s revenue for the quarter was up 333.6% on a year-over-year basis. During the same quarter last year, the firm earned ($0.24) EPS. sell-side analysts forecast that Second Sight Medical will post -0.58 EPS for the current fiscal year.

A number of equities research analysts have recently commented on EYES shares. HC Wainwright set a $5.00 target price on Second Sight Medical and gave the company a “buy” rating in a research report on Monday, February 5th. Zacks Investment Research raised shares of Second Sight Medical from a “sell” rating to a “hold” rating in a research note on Monday, January 8th.

COPYRIGHT VIOLATION NOTICE: This story was reported by Macon Daily and is owned by of Macon Daily. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://macondaily.com/2018/04/16/favorable-media-coverage-somewhat-unlikely-to-affect-second-sight-medical-eyes-stock-price-updated.html.

About Second Sight Medical

Second Sight Medical Products, Inc develops, manufactures, and markets prosthetic devices to restore functional vision to blind individuals in the United States, Italy, Germany, France, Canada, and Singapore. The company's product is the Argus II System, which treats outer retinal degenerations, such as retinitis pigmentosa.

Insider Buying and Selling by Quarter for Second Sight Medical (NASDAQ:EYES)

Receive News & Ratings for Second Sight Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply